• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE® EXCLUDER® AAA ENDOPROSTHESIS; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE® EXCLUDER® AAA ENDOPROSTHESIS; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT Back to Search Results
Catalog Number PLC181200
Medical Device Problem Codes Device Dislodged or Dislocated (2923); Device Endoleak (4074)
Health Effect - Clinical Codes Ruptured Aneurysm (4436); Clinical Endoleak (4843)
Date of Event 11/27/2024
Type of Reportable Event Serious Injury
Event or Problem Description
The following information was reported from the tgr23-02aa together aortic registry: on (b)(6) 2024, the patient underwent endovascular treatment of an abdominal aortic aneurysm using a gore® excluder® conformable aaa endoprosthesis (excc) trunk-ipsilateral leg component in the infrarenal abdominal aorta and a gore® excluder® aaa endoprosthesis contralateral leg component in the right common iliac artery.The devices were successfully navigated to the intended locations and successfully deployed.The patient tolerated the procedure.The patient was discharged to home on (b)(6) 2024.On (b)(6) 2024, a type iii endoleak and contained aneurysm rupture were observed.On (b)(6) 2024, a type iv endoleak was also reported.On the same date, a reintervention was performed whereby the device system was relined using a gore® excluder® trunk-ipsilateral leg component and bilateral iliac limbs.The aneurysm rupture was noted as resolved on (b)(6) 2024.The type iv endoleak was noted as resolved on (b)(6) 2024.
 
Additional Manufacturer Narrative
D.10.Concomitant medical products and therapy dates: hypercholesterolemia medication (not specified), hypertension medication (not specified).W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may have not been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
 
Additional Manufacturer Narrative
H.6.Investigation conclusions: code d16 updated to code d14.Additional information was received that the reported type iii endoleak occurred between the gore® excluder® conformable aaa endoprosthesis trunk-ipsilateral leg component (captured and reported under manufacturer report #3007284313-2025-03981) and a cook medical zenith alpha¿ thoracic endovascular graft.As there are no allegations of deficiency against the gore® excluder® aaa contralateral leg component related to the type iii endoleak, this information does not meet the definition of a reportable event or a complaint against the contralateral leg component.As there are no allegations of deficiency against this device related to the reported adverse events, this medwatch will be retracted.Additional devices included on this report are as follows: catalog #cxt321414/ serial # (b)(6)/ udi # (b)(4) which is captured in manufacturer report #3007284313-2025-03981.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE® EXCLUDER® AAA ENDOPROSTHESIS
Common Device Name
SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
Manufacturer (Section G)
MEDICAL SILICON VALLEY B/P
2890 de la cruz blvd.
santa clara CA 95050
Manufacturer Contact
jenna lopez
1505 n. fourth street
flagstaff, AZ 86004
9285263030
MDR Report Key22040820
Report Number3013164176-2025-02521
Device Sequence Number13026948
Product Code MIH
UDI-Device Identifier00733132618736
UDI-Public(01)00733132618736(17)270729
Combination Product (Y/N)N
Initial Reporter StateVA
Initial Reporter CountryUS
PMA/510(K) Number
P020004
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2024
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Study
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 09/10/2025
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Catalogue NumberPLC181200
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 04/17/2025
Supplement Date Received by Manufacturer09/10/2025
Initial Report FDA Received Date05/16/2025
Supplement Report FDA Received Date09/10/2025
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Date Device Manufactured07/30/2024
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
SEE H10 FOR LIST OF MEDICATIONS.
Outcome Attributed to Adverse Event Required Intervention;
Patient Age71 YR
Patient SexMale
Patient Weight79 KG
Patient EthnicityNon Hispanic
Patient RaceWhite
-
-